financetom
Business
financetom
/
Business
/
Exxon beats Q3 profit estimates on higher Guyana, Permian production
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exxon beats Q3 profit estimates on higher Guyana, Permian production
Oct 31, 2025 3:49 AM

HOUSTON (Reuters) -Exxon Mobil ( XOM ) beat Wall Street estimates for third-quarter earnings on Friday, underpinned by higher oil and gas production in Guyana and the Permian Basin which offset lower oil prices.

Adjusted earnings during the July-to-September quarter were $8.1 billion, or $1.88 per share, beating the analyst consensus estimate of $1.82 per share, according to data compiled by LSEG.

Brent crude prices averaged $68.17 in the third quarter, down about 13% from the same period last year.

Exxon, the top U.S. oil producer, has highlighted its portfolio of prolific assets and technology, which it says can improve oil recovery rates, allowing it to reap profits even during periods of lower crude prices.

"We delivered the highest earnings per share we've had compared to other quarters in a similar oil-price environment," Exxon CEO Darren Woods said in a statement.

He said production records were set in both the Permian Basin and Guyana, where the Yellowtail development was started up four months ahead of schedule and under budget.

"We've now started up eight of our 10 key 2025 projects, with the remaining two on track," Woods said.

Exxon paid $4.2 billion in dividends and repurchased $5.1 billion worth of shares during the quarter. It is on track to meet its annual share buyback target of $20 billion.

The company raised its fourth quarter dividend by 4% to $1.03 per share.

Production from the Permian Basin, the biggest U.S. oil field, was a record 1.7 million barrels of oil equivalent per day (boepd), while output from the lucrative Guyana oilfield surpassed 700,000 boepd.

During the quarter, Exxon acquired assets to begin producing synthetic graphite for batteries. 

Excluding acquisitions, Exxon said it expects its capital expenditure this year to be slightly below the low end of its $27 billion to $29 billion guidance range. 

The company recorded $510 million in restructuring costs during the quarter.

Global oil producers have experienced a rocky year as OPEC+ has increased its oil output while a U.S.-led tariff war has clouded the outlook for global growth and oil demand, driving oil prices down in the third quarter from a year earlier. However, average U.S. natural gas prices rose about 38% from last year. 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Oct 17, 2025
TORONTO, Oct. 17, 2025 /PRNewswire/ -- Visionary Holdings Inc. ( GV ) , a Nasdaq-listed enterprise, announced today that it has completed the equity adjustment of Sikang (Guangzhou) Health Industry Investment Co., Ltd. (hereinafter referred to as the Joint Venture Company), a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd. (hereinafter referred to as Guangzhou Sikang), and officially...
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Oct 17, 2025
09:29 AM EDT, 10/17/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday that a new post-hoc analysis of a late-stage study showed clinically meaningful improvements in tardive dyskinesia symptoms in patients treated with Ingrezza at the lowest available dose of 40 mg. The company said 90% of participants who received continuous treatment for 48 weeks improved by at...
Form 8.3 - Spectris plc
Form 8.3 - Spectris plc
Oct 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
AbbVie Closes Bretisilocin Acquisition
AbbVie Closes Bretisilocin Acquisition
Oct 17, 2025
09:28 AM EDT, 10/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Friday it has closed the acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate bretisilocin. Bretisilocin is a psychedelic compound in phase 2 clinical development for the treatment of patients with moderate to severe major depressive disorder, AbbVie ( ABBV ) said. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved